StockRing: 11/15/09, (NASDAQ:BIIB), $46.72, "BUY" Biogen Idec Inc (BIIB) Stock on Sunday, November 15, 2009

Login    About Us    Our Blog    Our Twitter    Contact Us     11/15/09, (NASDAQ:BIIB), $46.72, "BUY" Biogen Idec Inc (BIIB) Stock  BIIB opened at $46.42 and it is $+0.22, (+0.47%). Today's trading range is $46.31 - 47.06. 1y target price is $49.67.  DOW     +0.72%    +73.00    10270.47           ENGLAND     +0.38%    +19.88    5296.38           JAPAN     -0.35%    -34.18    9770.31  NASDAQ     +0.88%    +18.86    2167.88           GERMANY     +0.40%    +22.87    5686.83           CHINA     +0.46%    +14.7    3187.647  S&P 500     +0.57%    +6.24    1093.48           FRANCE     -0.05%    -2.06    3806.01           INDIA     +0.92%    +152.8    16848.83  CANADA     +0.41%    +46.92    11407.68           ITALY     -1.09%    -174.00    15743.00           RUSSIA     -0.41%    -5.85    1419.49  MEXICO     +0.79%    +242.24    31002.090           SWISS     -0.07%    -4.68    6351.08           TAIWAN     -0.07%    -5.3    7665.63

Stocks Funds SYMBOL:    YouTube Our Blog 11/11/09 StockRing Urgent Advice: Buy stocks on 11/12/09 - expect gains this week !!!    Option Exp: SAMPLE ! Option Exp:    EUROs for $1 DOLLAR: 3 MONTHS       Receive FRESH Daily Updates for 17 StockRing Reports for $30/month !!! 1. Dow Jones Index - 30 Stocks on 11/12/2009:  Buy   93% or 28   Hold   7% or 2   Sell   0% or 0 stocks     2. World Markets - 72 Indexes on 11/11/2009:  Buy   63% or 44   Hold   21% or 15   Sell   16% or 11 indexes 3. Best Brands - 200 stocks on 11/12/2009:  Buy   76% or 152   Hold   17% or 33   Sell   7% or 14 stocks 4. Hot News - 200 stocks on 11/8/2009:  Buy   47% or 93   Hold   23% or 46   Sell   30% or 60 stocks 5. Big Movers - 200 stocks on 11/14/2009:  Buy   69% or 137   Hold   23% or 47   Sell   8% or 15 stocks 6. Top Hitters - 200 stocks on 11/11/2009:  Buy   77% or 153   Hold   15% or 31   Sell   8% or 15 stocks 7. S&P 500 Index - 500 Stocks on 7/21/2009:   Buy   68% or 341   Hold   21% or 106   Sell   11% or 53 stocks 8. S&P 400 Mid Cap - 400 Stocks on 7/21/2009:  Buy   73% or 292   Hold   15% or 61   Sell   12% or 47 stocks 9. S&P 600 Small Cap - 600 Stocks on 4/18/2009:  Buy   66% or 395   Hold   26% or 156   Sell   8% or 49 stocks 10. Nasdaq Telecom - 164 Stocks on 7/24/2009:  Buy   49% or 81   Hold   35% or 56   Sell   16% or 27 stocks 11. Nasdaq Computer - 440 Stocks on 7/22/2009:  Buy   60% or 263   Hold   26% or 115   Sell   14% or 62 stocks 12. Nasdaq Finance - 180 Stocks on 7/24/2009:  Buy   61% or 109   Hold   6% or 12   Sell   33% or 59 stocks 13. NYSE International - 100 Stocks on 7/21/2009:  Buy   58% or 58   Hold   34% or 34   Sell   8% or 8 stocks 14. Legg Mason Mutual - 346 Funds on 10/6/2009:  Buy   38% or 133   Hold   51% or 176   Sell   11% or 37 funds 15. T. Row Price Mutual - 161 Funds on 10/6/2009:  Buy   52% or 84   Hold   46% or 73   Sell   2% or 4 funds 16. London FTSE 100 - 94 Stocks on 4/1/2009:  Buy   20% or 19   Hold   50% or 47   Sell   30% or 28 stocks 17. Canada Toronto - 209 Stocks on 4/18/2009:  Buy   53% or 111   Hold   34% or 70   Sell   13% or 28 stocks                                              TOTAL RATINGS:   Buy   60% or 2493   Hold   27% or 1080   Sell   13% or 517 stocks Video: 6-24-09 - Dow 30 stocks Buy-Sell-Hold Ratings 11/15/2009  Sunday, November 15, 2009 (Irvine, California) Today StockRing.com Recommendation is to "BUY"for Biogen Idec Inc (NASDAQ:BIIB) Stock. BIIB stock opening price was $46.42 per share. Current price of NASDAQ:BIIB Stock is $46.72 per share and it is $+0.22, (+0.47%) today and it was trading in the daily range of $46.31 - 47.06 per share. Current Bid Price for (NASDAQ:BIIB) stock is $46.40 and the Ask Price is $47.40. In the last 52 weeks BIIB stock was trading in the range of $37.21 - 55.34. 50-Day Moving Average for (NASDAQ:BIIB) stock is $47.1251 and 200-Day Moving Average is $48.5821. On average analysts predict that One Year Target Estimated price for (NASDAQ:BIIB) stock is $49.67. Biogen Idec Inc (NASDAQ:BIIB) Market capitalization is $13.511B. (NASDAQ:BIIB) stock average daily volume is 3,187,210 shares per day. However, on last trading session of Nov 13, 2009 BIIB stock traded 2,806,803 shares. Also The Short Ratio for (NASDAQ:BIIB) stock is 2.00. On previous trading session BIIB Stock closed at $46.50 per share. Last year Biogen Idec Inc (NASDAQ:BIIB) before taxes (EBITDA) (ttm) earned $1.685B on total revenue of $4.319B. Earnings Per Share - EPS (ttm) for BIIB stock is 2.988. Also, (NASDAQ:BIIB) Stock Price Per Earnings ratio - P/E is 15.56. Thus, (NASDAQ:BIIB) Stock Price/Sales (ttm) ratio is 3.11 and Price/Book (mrq) ratio is 2.05. (NASDAQ:BIIB) Stock does NOT PAY any dividend. So at this time (NASDAQ:BIIB) Stock maintains Trailing Annual Dividend Rate at 0.00 . StockRing Recommendations for Biogen Idec Inc (NASDAQ:BIIB) Stock are updated daily here http://www.StockRing.com/sr/StockDetail.asp?StockName=BIIB If you would like to receive Buy-Sell-Hold ratings for over 50,000 stocks, mutual funds, and ETFs go to StockRing web site: http://www.StockRing.com. BIIB Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max   News    Options!   More Info 11/15/2009 1 Year Stock market price chart for Biogen Idec Inc (NASDAQ:BIIB) Stock on Sunday, November 15, 2009    1 Year Dow Jones Chart 1 Year S&P 500 Chart 1 Year Nasdaq Chart 1 Year Canada Chart 11/15/2009 5 days Stock market price chart for Biogen Idec Inc (NASDAQ:BIIB) Stock on Sunday, November 15, 2009    5 Days Dow Jones Chart 5 Days S&P 500 Chart 5 Days Nasdaq Chart 5 Days Canada Chart BIIB Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max   News    Options!   More Info 11/15/2009 Stock market price quote data for Biogen Idec Inc (NASDAQ:BIIB) Stock on Sunday, November 15, 2009 Last Trade: 46.72 Trade Time: Nov 13 Change: +0.22, (+0.47%) Prev Close: 46.50 Open: 46.42 Bid: 46.40 Ask: 47.40 1y Target Est: $49.67 50-Day Moving Average: 47.1251 200-Day Moving Average: 48.5821 Short Ratio: 2.00 Trailing Annual Dividend Rate: 0.00 Day's Range: 46.31 - 47.06 52wk Range: 37.21 - 55.34 Volume: 2,806,803 Avg Vol: 3,187,210 Market Cap: 13.511B P/E (ttm): 15.56 EPS (ttm): 2.988 Div & Yield: 0.00 (N/A%) Revenue (ttm): 4.319B Earnings before Tax (EBITDA) (ttm): 1.685B Price/Sales (ttm): 3.11 Price/Book (mrq): 2.05 Receive FRESH Daily Updates for 17 StockRing Reports for $30/month !!!    EUROs for $1 DOLLAR: 3 MONTHS       Biogen Idec Inc (NasdaqGS: BIIB) Company Information Biogen Idec Inc. 14 Cambridge Center Cambridge, MA 02142 United States - Map Phone: 617-679-2000 Fax: 617-679-2617 Web Site: http://www.idecpharm.com Biogen Idec Inc (NasdaqGS: BIIB) DETAILS Index Membership: S&P 500 S&P 1500 Super Comp Nasdaq 100 Biogen Idec Inc (NasdaqGS: BIIB) Sector: Healthcare Biogen Idec Inc (NasdaqGS: BIIB) Industry: Biotechnology Biogen Idec Inc (NasdaqGS: BIIB) Full Time Employees: 4,700 Biogen Idec Inc (NasdaqGS: BIIB) BUSINESS SUMMARY Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. The company?s marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkin?s Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb, a Phase III clinical trial product for the treatment of relapsed NHL; Anti-CD23 MAb, a Phase II/III clinical trial product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia; and ADENTRI, a Phase III clinical trial product for acute decompensated heart failure patients with renal insufficiency. The company?s products under preclinical stage comprise BIIB014, Daclizumab, CDP323, Humanized Anti-CD20 MAb, PEG-IFN beta 1a, Neublastin, and LINGO for neurology; Volociximab, Hsp90 Inhibitor, GA101, Anti-IGF-1R, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; BG-12, Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for autoimmune and inflammatory diseases; and ADENTRI and Aviptadil for cardiovascular diseases. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; mondoBIOTECH, AG; Alnylam Pharmaceuticals, Inc.; UCB, S.A.; Facet Biotech Corporation; Sunesis Pharmaceuticals, Inc.; Vernalis plc; Vetter Pharma-Fertigung GmbH & Co. KG; and Schering AG, as well as a definitive agreement with AVEO Pharmaceuticals Inc. The company was founded in 1985 and is based in Cambridge, Massachusetts. Biogen Idec Inc (NasdaqGS: BIIB) KEY EXECUTIVES, SALARIES and BONUSES Mr. James C. Mullen , Age: 50 Chief Exec. Officer, Pres Salary: $ 3.59M Bonus: $ 17.81M Dr. Phillip A. Sharp Ph.D., Age: 64 Co-Founder Salary: $ 77.00K Bonus: N/A Mr. Paul J. Clancy , Age: 47 Chief Financial Officer and Exec. VP of Fin. Salary: $ 1.64M Bonus: $ 0 Mr. Robert Hamm M.A., Age: 57 Chief Operating Officer and Exec. VP of Pharmaceutical Operations & Technology Salary: $ 1.55M Bonus: $ 2.77M Mr. John M. Dunn J.D., Age: 56 Exec. VP of New Ventures Salary: N/A Bonus: N/A 1. Dow Jones Index - 30 Stocks on 11/12/2009:  Buy   93% or 28   Hold   7% or 2   Sell   0% or 0 stocks     2. World Markets - 72 Indexes on 11/11/2009:  Buy   63% or 44   Hold   21% or 15   Sell   16% or 11 indexes 3. Best Brands - 200 stocks on 11/12/2009:  Buy   76% or 152   Hold   17% or 33   Sell   7% or 14 stocks 4. Hot News - 200 stocks on 11/8/2009:  Buy   47% or 93   Hold   23% or 46   Sell   30% or 60 stocks 5. Big Movers - 200 stocks on 11/14/2009:  Buy   69% or 137   Hold   23% or 47   Sell   8% or 15 stocks 6. Top Hitters - 200 stocks on 11/11/2009:  Buy   77% or 153   Hold   15% or 31   Sell   8% or 15 stocks 7. S&P 500 Index - 500 Stocks on 7/21/2009:   Buy   68% or 341   Hold   21% or 106   Sell   11% or 53 stocks 8. S&P 400 Mid Cap - 400 Stocks on 7/21/2009:  Buy   73% or 292   Hold   15% or 61   Sell   12% or 47 stocks 9. S&P 600 Small Cap - 600 Stocks on 4/18/2009:  Buy   66% or 395   Hold   26% or 156   Sell   8% or 49 stocks 10. Nasdaq Telecom - 164 Stocks on 7/24/2009:  Buy   49% or 81   Hold   35% or 56   Sell   16% or 27 stocks 11. Nasdaq Computer - 440 Stocks on 7/22/2009:  Buy   60% or 263   Hold   26% or 115   Sell   14% or 62 stocks 12. Nasdaq Finance - 180 Stocks on 7/24/2009:  Buy   61% or 109   Hold   6% or 12   Sell   33% or 59 stocks 13. NYSE International - 100 Stocks on 7/21/2009:  Buy   58% or 58   Hold   34% or 34   Sell   8% or 8 stocks 14. Legg Mason Mutual - 346 Funds on 10/6/2009:  Buy   38% or 133   Hold   51% or 176   Sell   11% or 37 funds 15. T. Row Price Mutual - 161 Funds on 10/6/2009:  Buy   52% or 84   Hold   46% or 73   Sell   2% or 4 funds 16. London FTSE 100 - 94 Stocks on 4/1/2009:  Buy   20% or 19   Hold   50% or 47   Sell   30% or 28 stocks 17. Canada Toronto - 209 Stocks on 4/18/2009:  Buy   53% or 111   Hold   34% or 70   Sell   13% or 28 stocks                                              TOTAL RATINGS:   Buy   60% or 2493   Hold   27% or 1080   Sell   13% or 517 stocks 11/15/2009 Latest stock market news data for Biogen Idec Inc (NASDAQ:BIIB) Stock on Sunday, November 15, 2009 DIARY - U.S. Company Meetings for Friday Nov 13, 2009 Reuters - Nov 13, 2009 DATE GMT SYMBOL EVENT TITLE 13 Nov 1500 (AHPI.O) Allied Hlthcr Products Shareholders Meeting 13 Nov 1500 (AUXL.O) Auxilium Pharma.s at Credit Suisse Hlthcr Conf 13 Nov 1600 (BEC) Beckman Coulter ... Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching BNET - Nov 12, 2009 By David Phillips | Nov 12, 2009 On November 2, Biogen Idec updated the prescribing label for its blockbuster multiple sclerosis drug Tysabri (natalizumab) after consultation with the FDA. Aside ... Biogen Idec to Present at the Annual Credit Suisse Healthcare Conference Trading Markets - Nov 12, 2009 Nov 12, 2009 (Close-Up Media via COMTEX) -- BIIB -- Biogen Idec Inc. has announced that its presentation at the 2009 Annual Credit Suisse Healthcare Conference will be webcast live via the ... Biogen Rethinking Disclosure Policies On MS Drug Tysabri Wall Street Journal - Nov 11, 2009 By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Biogen Idec Inc. (BIIB) is re-evaluating the way it communicates new cases of a rare brain infection in patients on multiple sclerosis ... Biogen, Elan, Roche In Brain Infection Consortium - EasyBourse.com Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead Sciences, Biogen Idec and Acorda Therapeutics Business Wire - Nov 10, 2009 CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon (NYSE: ACL), Novartis (NYSE: NVS ... Big Pharma And Biotech - Industry Outlook istockAnalyst.com - Nov 9, 2009 The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III ... Biogen Idec to Present at the Lazard Capital Markets 6 th Annual Healthcare Conference Business Wire - Nov 9, 2009 CAMBRIDGE, MASS.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ/BIIB) announced today that its presentation at the Lazard Capital Markets 6 th Annual Healthcare Conference will be webcast live, via ... Option Activity Alert: Call Buying Climbs on Biogen Idec Inc. - Schaeffers Research NASDAQ - Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference - Ad-Hoc-News Trading Markets New Report Just Published Biogen Idec Inc - Detailed Product Pipeline Live-PR.com - Nov 9, 2009 (live-PR.com) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. contain detailed information on pipelines by ... Biogen Updates Tysabri Label To Reflect Risk With Longer Use Wall Street Journal - Nov 6, 2009 By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Biogen Idec Inc. (BIIB) amended the US label of multiple sclerosis treatment Tysabri, sold with Elan Corp. PLC (ELN), on Friday to ... Elan, Biogen change Tysabri label due to PML risk - Reuters New label says Tysabri risks increase over time - Boston Globe Biogen Idec Inc (BIIB) COO Robert A Hamm sells 2,854 Shares GuruFocus.com - Nov 5, 2009 COO of Biogen Idec Inc (BIIB) Robert A Hamm sells 2,854 shares of BIIB on 11/04/2009 at an average price of $42.81 a share. IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged ... RTT News Biogen Idec 3Q Net Up 34%; Cautious Rev View Given Wall Street Journal Biogen Idec Inc.'s (BIIB) third-quarter profit rose 34%, as earnings topped expectations amid cost-cutting and strong sales of the biotechnology company's ... All Tysabri, All the TimeMotley Fool Biogen Idec Reports Third Quarter 2009 ResultsPharmaLive.com (press release) Biogen Q3 net income, revenue increaseMass High Tech RTT News -Wall Street Journal all 254 news articles » Option Activity Alert: Call Buying Climbs on Biogen Idec Inc. Schaeffers Research Meanwhile, BIIB's Schaeffer's put/call open interest ratio (SOIR) confirms the apparently upbeat bias revealed by recent ISE option volume. The stock's SOIR ... and more » BEFORE THE BELL:US Stock Futures Up Ahead Of Earnings Wall Street Journal Biogen Idec Inc. (BIIB) extended its tender offer for Facet Biotech Corp. (FACT) shares by nearly two months to Dec. 16, despite Facet's repeated insistence ... and more » Wider Loss for Alnylam - Analyst Blog Benzinga The company has entered into collaborations or deals with big pharmaceutical players like Novartis (NVS), Biogen Idec (BIIB), Roche and Takeda to further ... and more » Biogen's Tysabri Disclosure Policies Raise Questions Wall Street Journal NEW YORK (Dow Jones)--Biogen Idec Inc.'s (BIIB) refusal to disclose new cases of a severe brain infection among ... and more » 4-Star Stocks Poised to Pop: Elan msnbc.com Here's an excerpt: Its primary money maker, Tysabri that it partners with [Biogen Idec (Nasdaq: BIIB)] in producing, has continued to receive warnings that ... and more » Elan Hits 3Q Net Pft On Cost Cuts, Tysabri Wall Street Journal Davy Research said better characterizing the PML risk profile remains the key priority for BIIB/Elan. "In the near term, we believe the stock has scope to ... and more » Caliper Life Sciences Reports Third Quarter 2009 Results CNNMoney.com (press release) In addition, the Company reaffirmed its expectation to achieve positive earnings before interest, taxes, depreciation, amortization and stock-based ... and more » Pre-Market Stock Upgrades/Downgrades Nov 2, 2009 Wall Street Pit (blog) Popular Inc. (BPOP) upgraded to Buy at Sterne Agee ; price target set at $3 Biogen Idec (BIIB) upgraded to Buy at Jefferies & Co. ; price target set at $50 ... Upgrades & Downgrades: Analysts Shopping at NordstromMinyanville.com all 3 news articles » Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead Sciences, Biogen ... Business Wire (press release) In the biotech space, we are positive on names like Gilead Sciences (Nasdaq: GILD) and Biogen Idec (Nasdaq: BIIB) even though we have Neutral ... Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead Sciences, Biogen ...Zacks.com all 6 news articles » 11/15/2009 News from StockRing Blog about Biogen Idec Inc (NASDAQ:BIIB) Stock on Sunday, November 15, 2009 12/7/2008 StockRing advise: SELL 33% or 163, HOLD 47% or 237, BUY ... BIIB, BUY - Biogen Idec Inc. (NasdaqNM : BIIB), Dec 5, 44.25, +2.55, +6.12%, 3706666. 63. BJS, SELL - BJ Services Company (NYSE : BJS), Dec 5, 9.39, +0.13, +1.40%, 10829207. 64. BK, HOLD - The Bank of New York Mellon. ... 12/7/2008 stockring advise: sell 33% or 163, hold 47% or 237, buy ... biib, buy - biogen idec inc. (nasdaqnm : biib), dec 5, 44.25, +2.55, +6.12%, 3706666. 63. bjs, sell - bj services company (nyse : bjs), dec 5, 9.39, +0.13, +1.40%, 10829207. 64. bk, hold - the bank of new york mellon. ... 12/25/2008 stockring advise: sell 35% or 176, hold 39% or 195, buy ... biib, hold - biogen idec inc. (nasdaqnm : biib), dec 24, 47.20, +0.15, +0.32%, 544563. 63. bjs, hold - bj services company (nyse : bjs), dec 24, 10.45, -0.07, -0.67%, 1841742. 64. bk, sell - the bank of new york mellon. ... 11/22/2008 stockring buy-sell-hold ratings for s&p 500 stocks biib, sell - biogen idec inc. (nasdaqnm : biib), nov 20, 39.77, -1.29, -3.14%, 4586278. 63. bjs, super sell - bj services company (nyse : bjs), nov 20, 8.76, -1.73, -16.49%, 11773970. 64. bk, sell - the bank of new york mellon. ... 12/3/2008 stockring advise: sell 39.4% or 197, hold 50.4% or 252 ... biib, super sell - biogen idec inc. (nasdaqnm : biib), 4:00pm, 42.12, +0.69, +1.67%, 4186983. 63. bjs, sell - bj services company (nyse : bjs), 4:00pm, 9.95, +0.22, +2.26%, 7414986. 64. bk, sell - the bank of new york mellon. ... 12/7/2008 stockring advise: sell 33% or 163, hold 47% or 237, buy ... biib, buy - biogen idec inc. (nasdaqnm : biib), dec 5, 44.25, +2.55, +6.12%, 3706666. 63. bjs, sell - bj services company (nyse : bjs), dec 5, 9.39, +0.13, +1.40%, 10829207. 64. bk, hold - the bank of new york mellon. ... 12/7/2008 stockring advise: sell 33% or 163, hold 47% or 237, buy ... biib, buy - biogen idec inc. (nasdaqnm : biib), dec 5, 44.25, +2.55, +6.12%, 3706666. 63. bjs, sell - bj services company (nyse : bjs), dec 5, 9.39, +0.13, +1.40%, 10829207. 64. bk, hold - the bank of new york mellon. ... 12/3/2008 stockring advise: sell 39.4% or 197, hold 50.4% or 252 ... biib, super sell - biogen idec inc. (nasdaqnm : biib), dec 3, 42.12, +0.69, +1.67%, 4186983. 63. bjs, sell - bj services company (nyse : bjs), dec 3, 9.95, +0.22, +2.26%, 7414986. 64. bk, sell - the bank of new york mellon. ...    Abele John   Abrams George    Abrams Jonathan   Ackermann Josef   ACUSHNET   A.I.G.   AIG   Albright Madeleine   AMAZON.COM   AMERITRADE   Andelman David   Andreessen Marc   Angwin Julia   Anthony Jim   APAX PARTNERS   ARCH VENTURE PARTNERS   ARONSSON GROUP   Ashworth Paul   AT&T   AVON BOOKS   Bair Sheila   BANK OF AMERICA   BARCLAYS   Barton Rich   Bassett Angela   BEAR STEARNS   Begich Mark   Bell Bryon   Bennett Tony   Berke Barry   Bernanke Ben   BET   BETSEY JOHNSON   Biaggi Mario   Bierut Michael   Biondi Frank   Blankfein Lloyd   Blinder Alan   Bock Jeff   BOEING   Boncompagni Tatiana   Bond Adam   Bond Victoria   Born Brooksley   BOSTON SCIENTIFIC   BP   Brazinski Daniel   Breslin Jimmy   Brody Kenneth   Brown Greg   Burkle Ron   Burow Kristina   Burrough Bryan   Bush George W.   Callan Erin   CALLAWAY GOLF   CARLYLE GROUP    CASCADE INVESTMENT   Cassano Joseph   Dauman Philippe   De Niro Robert   Dickerson Paul   Dillon Harrison   DISNEY   Dodd Christopher   Donaldson William   Douglas Michael   Draghi Mario   DREAMWORKS SKG   DUTTON   Dykstra Lenny   Eisner Michael   ELECTRONIC ARTS   Emanuel Rahm   ENRON   ESL INVESTMENTS   Evans Robert   Falcone Philip   FANNIE MAE   FEDERATED DEPARTMENT   STORES   FINANCO   Flavin Jennifer   Fleckenstein Bill   Foreman George   Frank Barney   Frears Stephen   FREDDIE MAC   Freston Tom   Friedman Stephen   Fuld Dick   Furman Roy   Garavani Valentino   Gates Bill   Geffen David   Geithner Tim   GENERAL MOTORS   Gensler Gary   Gerdeman Fred   Gibson Charles   GLASSDOOR   GLG PARTNERS   GOLDMAN SACHS   Greenspan Alan   Greenspan Glenn   Grey Brad   Griffin Kathy   Griffin Ken   Grove Andy   HALSTON   HARBINGER CAPITAL   PARTNERS   Harrison Gilbert   Harrison Mya   HCR MANORCARE   HEWLETT-PACKARD   HILCO CONSUMER   CAPITAL   Hohman Robert   JEFFRIES & CO.   Jobs Steve   Johnson Magic   Johnson Robert   Jolie Angelina   Jordan Michael   JP MORGAN CHASE   Kaczynski Ted   Karan Donna   Kargman Jill   Karmazin Mel   Kashkari Neel   King Larry   Knowles Beyonce   KohlbergJerry   KopelmanArie   KopelsonAnne   KopelsonArnold   Korff Ira   Korff Kimberlee   Kurzman David   Lagrange Pierre   Lampert Eddie   Lansing Sherry   LEHMAN BROTHERS   LENDINGTREE   Levitt Arthur   Levy Leon   Liddy Ed   LINKEDIN   Little Edward   Loeb Allan   Lois George   LONG-TERM CAPITAL   MANAGEMENT   Lonski John   Lundgren Terry   MACYS   Madoff Bernie   Marcus Bernie   Marriott Bill   Maskin Eric   Mason Richard   MATTHEW WILLIAMSON   MAY DEPARTMENT   STORES   McCombs Red   McKinnon Mark   McLucas William   Meltzer Allan   MERRILL LYNCH   MGM   MICROSOFT   MIDWAY GAMES   Misner Jeff   Mitchell Andrea   Moglia Joe   Molinaro Sam   MOODYS INVESTORS   SERVICE   Moonves Leslie   Morgan Peter   MORGAN STANLEY   Moses Herb   MOTOROLA   Mozilo Angelo   Murdoch Rupert   Murphy Eddie   MYSPACE   Nader Ralph   Nardelli Bob   NATIONAL AMUSEMENTS   NEWS CORP.   Nicholas Pete   Nicklaus Tack   NICKLAUS DESIGN   NIKE   Norquist Grover   NRDC EQUITY PARTNERS   Obama Barack   ODYSSEY PARTNERS   Oman Brady   OPPENHEIMER & CO.   OReilly Bill   OReilly Tim   OVERTURE FILMS   Paese Michael   Palin Sarah   PALM   Pandit Vikram   PARAMOUNT PICTURES   Partnoy Frank   Pataki George   Paulson Henry   Paulson John   Preston Kelly   Purcell Philip   Pyle Jason   RBS GREENWICH CAPITAL   Reardon Roy   Redstone Brent   Redstone Eddie   Redstone Michael   Redstone Paula   Redstone Phyllis   Redstone Shari   Redstone Sumner   RELIANCE   RENAISSANCE TECHNOLOGIES   ROYAL DUTCH SHELL   Rubin Robert   SAC CAPITAL ADVISORS   SALTON   SAPPHIRE ENERGY   Schiff Stephen   Schrager Ian   Schumer Chuck   Schwartz Alan   Scott Lee   Shields Brooke   SHUTTERFLY   SIEMENS   Silverman Ben   Simons James   SIX APART   SOCIALIZR   SOLAZYME   Sorkin Aaron   Sorkin Andrew Ross   Soros George   Spielberg Steven   Spurlock Morgan   Stallone Sylvester   Stanley Stephen   Staubach Roger   Steel Robert   Steinberg Mark   Stern Andy   Stiglitz Joseph   ST. MARTINS PRESS   Stone Oliver   Sullivan Mark T.   Summers Lawrence   SUTTER HILL VENTURES   TACONIC CAPITAL PARTNERS   DESIGN TOMMY HILFIGER   Travolta John   Trump Ivanka   TSM CAPITAL   CENTURY FOX   AFRIKA   TYCO   UBS   UNITED ARTISTS   UNIVERSAL   VALENTINO FASHION   GROUP   VANTAGE   V AUSTRALIA   VENROCK ASSOCIATES   VIA COM   Volcker Paul   VONAGE   WACHOVIA   Wagner Paula   Wales Jimmy   Wallison Peter   WAL-MART   WarinJoseph   WARNER BROTHERS   WASHINGTON MUTUAL   Waters Maxine   Waxman Henry   Weinstein Bob   Weinstein Harvey   WEINSTEIN CO.   Weiser Stanley   Welch Jack   Welling Beau   Whitacre Ed   White Kevin   Whitehead John   Williams Brian   Wilson Victoria   WMS INDUSTRIES   Wolfson Jonathan    Copyright © 2009 StockRing.com. All rights reserved. Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.

Buy from S&P 500:
Akamai - AKAM
Amazon.com - AMZN
Big Lots - BIG


Sell from S&P 500:
Alcoa - AA
Autodesk - ADSK
Aflac - AFL


Buy from S&P 400 MidCap:
Carmax - KMX
99c Stores - NDN
Netflix - NFLX


Sell from S&P 400 MidCap:
Timken - TKR
Trinity - TRN
Aflac - AFL


Buy from S&P 600 SmallCap:
Coinstar - CSTR
Holly - HOC
Maximus - MMS


Sell from S&P 600 SmallCap:
Barnes - B
Cascade - CAE
Brightpoint - CELL


Buy from Nasdaq 100:
Baidu.com - BIDU
Verisign - VRSN
Yahoo - YHOO


Sell from Nasdaq 100:
Adobe - ADBE
Amgen - AMGN
Costco - COST


Buy from Nasdaq Telecom:
Adtran - ADTN
CalAmp - CAMP
KongZhong - KONG


Sell from Nasdaq Telecom:
iBasis - IBAS
Interphase - INPH
RCN Corp - RCNI


Buy from Nasdaq Biotech:
Eurand - EURX
Illumina - ILMN
Trimeris - TRMS


Sell from Nasdaq Biotech:
Antigenics - AGEN
Celera - CRA
Incyte - INCY


Buy from Nasdaq Computer:
eLoyalty - ELOY
LogicVision - LGVN
Macrovision - MVSN


Sell from Nasdaq Computer:
Amtech - ASYS
Bsquare - BSQR
Corel - CREL


Buy from Nasdaq Finance:
Elbit - EMITF
Chardan - CACA
Tree.com - TREE


Sell from Nasdaq Finance:
BancFirst - BANF
FirstMerit - FMER
Advanta - ADVNA